The ATLAS programme aims to promote and implement HIV self-testing (HIVST) in three West African countries: Côte d’Ivoire, Mali, and Senegal. During 2019–2021, in close collaboration with the national AIDS implementing partners and communities, ATLAS plans to distribute 500,000 HIVST kits through eight delivery channels, combining facility-based, community-based strategies, primary and secondary distribution of HIVST.
Considering the characteristics of West African HIV epidemics, the targets of the ATLAS programme are hard-to-reach populations: key populations (female sex workers, men who have sex with men, and drug users), their clients or sexual partners, partners of people living with HIV and patients diagnosed with sexually transmitted infections and their partners.
The ATLAS programme includes research support implementation to generate evidence for HIVST scale-up in West Africa.
The main objective is to describe, analyse and understand the social, health, epidemiological effects and cost-effectiveness of HIVST introduction in Côte d’Ivoire, Mali and Senegal to improve the overall HIV testing strategy (accessibility, efficacy, ethics).
ATLAS research is organised into five multidisciplinary workpackages (WPs):
Key Populations WP: qualitative surveys (individual in-depth interviews, focus group discussions) conducted with key actors, key populations, and HIVST users.
Index testing WP: ethnographic observation of three HIV care services introducing HIVST for partner testing.
Coupons survey WP: an anonymous telephone survey of HIVST users.
Cost study WP: incremental economic cost analysis of each delivery model using a top-down costing with programmatic data, complemented by a bottom-up costing of a representative sample of HIVST distribution sites, and a time-motion study for health professionals providing HIVST.
Modelling WP: Adaptation, parameterisation and calibration of a dynamic compartmental model that considers the varied populations targeted by the ATLAS programme and the different testing modalities and strategies.
ATLAS is the first comprehensive study on HIV self-testing in West Africa. The ATLAS programme focuses particularly on the secondary distribution of HIVST. This protocol was approved by three national ethic committees and the WHO’s Ethical Research Committee.
In West Africa, HIV prevalence ranges from 0.3 to 3.4% in the general adult population . These epidemics are usually classified as “generalised” (above 1%). Despite this, key populations (female sex workers (FSW), men who have sex with men (MSM), people who use injectable drugs (PWuID)) and vulnerable populations (depending on the country: men in uniform, mobile workers, clients of FSW, etc.) are important to local HIV transmission dynamics .
In 2019, only 68% of people living with HIV (PLHIV) in West Africa were aware of their HIV status, 58% were on antiretroviral (ARV) therapy and 45% had an undetectable viral load , all of which are far from the levels required to achieve epidemic control. The first step of the HIV care cascade, HIV testing, is also the most important gap to fill to attain the 90–90-90 UNAIDS targets . The WHO/UNAIDS meeting held in Dakar in November 2017 highlighted the urgent need to accelerate progress on HIV testing in West Africa and to adopt innovative and tailored testing approaches to reach those who have not yet been tested .
Over the past decade, considering the concentrated aspect of local epidemics, national AIDS programmes have increasingly developed actions specifically targeting key populations who are particularly vulnerable to HIV acquisition and transmission. Community-based activities have thus improved access to HIV testing among those reached by peer educators, FSW and MSM in particular, while activities targeting PWuID were less common.
Despite these initiatives, key populations remain difficult to reach, particularly hidden MSM and occasional FSW . While HIV stigma and distance from services are common barriers to HIV testing for the entire population in West Africa, key populations exhibit lower HIV testing rates and face specific additional barriers due to socially stigmatised and even illegal practices [6,7,8,9].
Epidemic dynamics are complex and understanding heterogeneity in the risk of HIV acquisition and transmission is crucial for maximising the impact of the HIV response . Approximately 30% of new infections are estimated to occur among people who engage in low-risk behaviours but have partners with high-risk behaviours, such as unprotected sex with a partner whose HIV status is unknown or multiple unprotected sexual partnerships . According to two modelling studies, 44% of new infections arising in Côte d’Ivoire from 2005 to 2015 occurred in partnerships between clients and their non-FSW female partners , while over the same period, 38% of new HIV infections occurring in Dakar and Senegal were within non-commercial partnerships between FSW and clients .
HIV self-testing: an innovative and powerful tool for testing with remaining research gaps
HIV self-testing (HIVST) is a process in which the user takes a sample (oral fluid or blood), performs the HIV test, and then interprets the result alone, often in a private setting (WHO 2016).
Several studies have shown that, for many users, HIVST promotes discretion and autonomy, HIV test uptake by first-time testers and is associated with increased testing frequency [14,15,16,17]. HIVST has high acceptability, particularly among key populations and those who do not test regularly [18,19,20,21].
Distribution strategies for HIVST can be based on a primary distribution where the HIVST kit is given directly to the person who will perform the test [20, 22] or on a secondary distribution where the HIVST is given to a relay person who will redistribute it to one or many of his/her contacts. Secondary distribution makes it possible to reach hidden key populations, such as clients of FSW [23, 24], partners of MSM , or index partners of pregnant women [26,27,28] who are not routinely tested. The ability of primary contacts to distribute HIVST kits to their contacts is not guaranteed, as secondary distribution may be limited due to specific barriers and may be accompanied by social consequences, such as acts of violence against FSW by their clients [22, 23].
In sub-Saharan Africa, partners of PLHIV are among the priority target populations for testing because they are at particular risk for HIV infection. Indeed, some studies estimate that up to two-thirds of new infections occur in heterosexual couples . In many couples, one or both partners do not know their HIV status . Difficulties in disclosing one’s status due to HIV-related stigma, leading to low rates of partner sharing, have been reported [31,32,33,34,35]. HIVST is a complementary tool to other HIV testing support activities for partners of PLHIV. HIVST can be a way to initiate a dialogue on HIV between partners when a partner is not informed. This disclosure can have consequences for the couple (separation, violence, dialogue, support) [36, 37] and also for the partner’s willingness to undergo HIVST. In all these issues, the gender dimension is an important element. Indeed, men and women do not manage disclosure of HIV status similarly, nor do they manage the relationship to HIV test results in the same way .
Sexually transmitted infections (STI) counselling provides an opportunity for HIV testing for both patients and their partners . People infected with sexually transmitted infections (STIs) are also at higher risk for HIV infection . It has been shown that the use of STI counselling among individuals who thought they were at risk of HIV infection was higher than that among those who did not think they were at risk. Furthermore, although HIV testing at STI consultations is recommended, the percentage of testing initiated in this context remains low. A recent study in Côte d’Ivoire found that only 28% of patients who had an STI medical consultation were offered HIV testing .
Only a few pilot experiments in HIV self-testing have been implemented in West Africa. There is a strong demand for the implementation of new innovative prevention and testing tools, such as HIVST, in the region [42, 43]. One study in Senegal showed that HIVST represents an approach that reached first-time testers and those who had not been tested recently . The introduction of HIV self-testing in West Africa may help to remove some of the barriers faced by key and vulnerable populations and improve their access to HIV testing, as observed in other parts of Africa [25, 45].
The ATLAS programme
Following the WHO recommendations and the experience gained in East and Southern Africa through the STAR programme , Unitaid and other countries wished to promote and implement HIV self-testing in West Africa through funding the ATLAS programme in Côte d’Ivoire, Mali and Senegal. During 2019–2021, ATLAS plans to dispense more than 500,000 HIV self-test kits. Only oral HIVST OraQuick HIV Self-Test® (OraSure Technologies, LLC Bethlehem) will be used as it is pre-qualified by WHO and has been validated by the three countries of intervention.
In each country, the provision of HIVST is complementary and integrated into existing HIV testing strategies and will be performed by field workers already engaged in testing activities financed by the Global Fund or PEPFAR. Different delivery channels and target populations for each country have been developed in collaboration with the countries’ stakeholders (national AIDS programmes/councils, international institutions, including WHO, international and national NGOs involved in local HIV programmes, civil society, communities).
Eight delivery channels have been selected for the ATLAS programme after discussion with various stakeholders (Fig. 1). Five delivery channels adopt a facility-based strategy (delivery of HIVST in a health facility), and three delivery channels adopt a community-based strategy through field activities.
Due to the West African epidemiological and social context, the ATLAS programme plans to promote secondary distribution in each of the eight delivery channels to reach beyond those reached through primary distribution by health care workers and peer educators.
Implementation of HIVST in West Africa raises specific questions related to the cultural, social, economic, and epidemiological contexts of this region. Furthermore, questions remain regarding specific delivery channels and secondary distribution in particular.
The social dimensions of HIV testing in general, and of HIVST in particular, play an important role and impact the acceptability and uptake of HIVST in different populations and contexts . Regardless of the perceptions and attitudes of populations and health workers, the quality and organisation of health services is an essential factor that can promote or limit access to testing. More generally, documentation of the factors facilitating or limiting HIVST is a way to support the implementation of tailored activities.
Because of the large proportion of HIVST secondary distribution, routinely collected programmatic data will be insufficient to describe the sociodemographic profiles of HIVST users, as well as their trajectories of care following a reactive HIVST. In addition to its health impact, HIVST could have other social consequences, harmful or beneficial, not foreseen by the health system. For example, some people could be coerced by their partner to be tested, and a reactive result could be a source of violence. Despite challenges, documenting the profile of HIVST users and the social and health consequences of HIVST is essential.
With HIVST being integrated with other conventional HIV testing strategies, it is important to evaluate the routine incremental costs of adding HIVST to existing services and its associated epidemiological impacts for each delivery channel. These data are essential for national programmes and technical and financial partners to prepare for scaling up by comparing different possible scenarios of distribution channels, population and estimating cost-effectiveness and budgetary impacts.
The primary objective of the research component embedded in the ATLAS programme is to describe, analyse and understand the social, health, epidemiological and economic effects of the introduction of HIV self-testing in Côte d’Ivoire, Mali and Senegal to improve the availability of testing (accessibility, efficacy and ethics).
This primary objective can be subdivided into six secondary objectives:
➔ Identify the social, cultural and organisational factors facilitating and limiting the primary and secondary distribution of HIV self-tests and their use/appropriation by the different actors concerned (programme or project manager and NGO representative, delivery agents, primary contacts, secondary contacts).
➔ Establish the socio-behavioural profile and HIV testing history of HIV self-test users and their care history in the event of a reactive self-test.
➔ Analyse the positive and negative social and health consequences of the introduction of HIV self-testing for individuals, communities and the health system.
➔ Estimate the incremental costs of dispensing HIV self-tests per delivery channel.
➔ Model the epidemiological impacts of the ATLAS programme and different scaling scenarios on epidemic dynamics.
➔ Estimate the medium- and long-term cost-effectiveness and budgetary impact of different strategies for scaling-up.
Methods and analysis
This protocol is based on version 2.1 of the ATLAS research protocol. In case of future updates, the latest version of the protocol will be available on https://atlas.solthis.org/recherche/.
The ATLAS research component brings together multidisciplinary researchers from different institutions in partnership with the different operational teams of the programme.
Research activities embedded within the ATLAS programme are organised into 5 work packages: (i) a qualitative survey on HIVST focused on key populations and based on qualitative individual and group interviews with key implementers, members of key population communities and HIVST users; (ii) an ethnography on the integration of HIVST for screening PLHIV’s partners in three HIV care clinics; (iii) an anonymous telephone survey of HIVST users recruited through an invitation on HIVST kits to call a toll-free number; (iv) an economic survey of HIVST incremental costs with cost collections from a sample of HIVST dispensing sites and a time and motion study; (v) an epidemiological modelling (dynamic compartmental model) of the three countries and of the health and economic impacts of different scaling scenarios.
Key populations WP
The specific objectives of this WP are to identify factors that promote and limit the integration of HIV self-testing into the health care system and the primary and secondary distribution of HIV self-tests in key populations (FSW, MSM and PWuID); to analyse perceptions, attitudes, ownership, and experience of HIV self-testing; and to analyse the social effects of HIV self-testing at the individual, collective and health system level.
Qualitative surveys will be conducted (individual in-depth interviews and focus group discussions) in the three countries with (i) key actors in testing programmes targeting key populations (FSW, MSM, PWuID); (ii) members of the three key population communities and (iii) HIV self-test users recruited either by peer educators or through the Coupons survey. The different sub-studies are described in Table 3 and will be conducted sequentially. They will be complemented by document review (press articles, HIVST promotional documents).
Index testing WP
The specific objectives of this WP are to describe how HIV care services and healthcare professionals integrate HIV self-testing for sexual partners of PLHIV; to study how PLHIV negotiate issues around the HIV self-testing proposal to their partner(s); to analyse perceptions, uses and modalities of use of HIV self-tests by partners; and to identify individual, marital and social impacts.
This WP will use anthropological methods, consisting primarily of ethnographic observations and individual in-depth interviews.
The study survey will be conducted in all three ATLAS countries, with an ethnographic study in three HIV clinics (one per country) where HIVST is offered as part of the ATLAS programme’s dispensing activities (2.5 months in each clinic). It will include both (i) observations of consultations, medical staff and any other activities organised in connection with the distribution of HIVST; and (ii) in-depth individual interviews with PLHIV followed in the service who were offered an HIVST to distribute to their partners, PLHIV partners who have accepted or refused HIVST and health staff.
At the project end, over 2 weeks, some health workers and patients interviewed during the ethnographic studies will be re-interviewed to evaluate HIVST appropriation by the different actors and the expected and unexpected repercussions and difficulties after several months of implementation.
The content of the interviews and observations will be subject to thematic analysis using the online content analysis software Dedoose. Data analysis will be based on a Grounded Theory approach , i.e., a theory developed by induction from a corpus of data. The analytical framework of this WP will be based on a sociological approach to gender .
Coupons survey WP
Specific objectives of the coupons survey are to document the socio-behavioural profile and screening history of HIV self-tests users; to identify the care trajectories of these HIV self-tests users following a reactive or indeterminate self-test; and to provide an empirical estimate of some parameters used by the WP Modelling. The survey was designed to enable data collection from HIVST end-users based on anonymity and voluntary participation through the establishment of an anonymous and free telephone platform in the three countries.
To be eligible for the study, participants must be of legal age to perform an HIV test by him/herself (i.e., 16+ years old in Côte d’Ivoire, 18+ in Mali and 15+ in Senegal) and have performed an HIVST.
The survey will be organised in collection waves with two phases each. A pilot study will be conducted before the implementation of the full survey.
Survey phase 1
During phase 1 of each wave, all HIVST kits distributed in the country through ATLAS, regardless of delivery channel, will contain an invitation to participate in the study (the “coupons”). Similarly, anyone calling the national HIV hotline during this period and reporting having performed an HIVST will be invited to participate in the coupons survey by calling the dedicated survey free phone number.
All HIVST kits distributed under the ATLAS programme will also be marked using a coloured sticker with a numbered code to identify the delivery channel and the technical implementation partner. During the telephone interview, the participant will be asked for the colour and number of the sticker to be able to associate each questionnaire with a dispensing channel.
When a person calls one of the study’s toll-free numbers, they will first be presented with the study and then asked to state orally whether they consent to participate (verbal consent, time-stamped). If consent is given, a 15-min questionnaire will be administered. This questionnaire will cover the participant’s socio-demographic characteristics, his or her HIV testing history, sexual practices, knowledge of HIVST, ease of use of the HIVST kit and the result of his/her self-test.
Survey phase 2
Phase 1 participants who reported a reactive or indeterminate HIVST result and who agreed to be contacted again will be called back 3 months after completion of the phase 1 questionnaire for the phase 2 questionnaire. This second questionnaire aims to document the participant’s care trajectory and, in particular, whether a confirmatory test has been performed and, if so, whether the person linked to HIV care and initiated antiretroviral treatment.
Cost study WP
Because HIVST is being added onto existing HIV testing programmes, the specific objectives of the cost WP are to estimate the incremental costs of providing HIVST; to compare the costs of HIVST to other HIV testing approaches; to model medium- and long-term scale-up costs; and to compare costs to expected epidemiological impacts (Modelling WP) to estimate the cost-effectiveness of these scale-up scenarios.
We will conduct an incremental HIVST cost analysis to capture economic costs (i.e., all resources used, including donated goods and services) of the intervention. We will also conduct a full economic cost analysis of a sample of conventional HIV testing sites where HIVST is being introduced. The analysis will follow the recommendations of the Global Health Cost Consortium, which sets standards for health costing studies .
Data collection includes (i) a top-down cost approach with programmatic cost data; (ii) a bottom-up cost approach with a representative sample of HIV self-tests distribution sites; and (iii) a time-motion study with a sample of dispensing agents (Table 4).
The analysis will take a provider’s perspective. We will estimate programme development, start-up, and implementation costs, capturing both capital costs (infrastructure, equipment, etc.) and recurrent costs (salaries, HIVST kits, etc.). The cost analysis will differentiate between the start-up phase (all costs incurred before the first HIV kits are distributed) and the “implementation” phase (one-year observation period following the beginning of HIVST kit distribution). For each country and delivery channel, the main output will be the total programme costs and average cost per HIVST kit delivered (HIVST cost), and per person tested for HIV/per HIV-positive case identified (HTS cost). Based on the observed costs of early implementation, we will model costs at scale and consider the budgetary impact of alternative HIV testing programme models.
The impact of HIVST is not limited to the diagnosis of PLHIV. By identifying more PLHIV unaware of their status (and identifying them more rapidly), there is potential to reduce the average length of time that a person is at risk of transmitting the virus. In this way, HIVST can reduce the morbidity and mortality of newly diagnosed infected people if they are promptly linked to care, as well as reducing onward transmission if they achieve viral load suppression .
Such medium- and long-term effects cannot be easily empirically measured, and mathematical models of HIV transmission dynamics offer a robust alternative. For example, different scenarios (with or without the introduction of HIVST, for example) can be compared to estimate incremental gains in new infections prevented, life-years gained, and deaths avoided. Diverse scenarios can be explored, and sensitivity analyses conducted. Epidemic modelling is a valuable tool for answering these types of questions and for providing insights into the possible impacts of different health policies related to HIVST. This tool is also essential for a better understanding of the current epidemic dynamics and improved focus of activities to be performed.
The specific objectives of the Modelling WP are to identify population groups most likely to acquire and transmit HIV and to identify their testing and diagnostic delays; to estimate the population impact of the introduction of HIVST in the three ATLAS countries, at the scale achieved by the ATLAS programme and under possible scale-up scenarios; and to estimate the cost-effectiveness of these scale-up scenarios and conduct sensitivity analysis.
Several existing dynamic models of HIV transmission that have already developed and calibrated to the HIV epidemic in West Africa will be leveraged [12, 13, 52, 53]. These models will be adapted to the idiosyncrasies of HIVST , parameterised, and calibrated to detailed epidemiological and intervention data collected as part of the ATLAS programme.
Briefly, the model will represent an open (15–59 years) and growing population stratified by four age groups (15–19, 20–24, 25–49, and 50–59 years). Also, different risk groups and levels of sexual activity will be considered: low- and high-risk women, low- and high-risk men, sex workers, clients of sex workers, men who have sex with men and women, and men who have sex exclusively with men. The model considers the age of sexual debut, as well as the migration and mortality due to HIV or other causes.
The model represents natural HIV progression from the initial/acute highly infectious phase to the chronic phase. The model also describes the treatment and care continuum: testing, management, and initiation of antiretroviral therapy. This description of the continuum of care helps to determine the three stages of the UNAIDS 90–90-90 target in each subpopulation group (Fig. 2).
Sexually active individuals at risk may acquire HIV infection at a rate that depends on their annual number of sexual partners and sexual acts, the type of sexual partners and sexual acts (vaginal or anal), the prevalence of HIV among their sexual partners and their stage of infection, and their initiation of treatment, the type of sex, and the rate of condom use.
Parameterisation and calibration
The model will have to be parameterised and calibrated for the three ATLAS countries. The model parameters come from four different areas: (i) demographic (age structure, mortality, etc.); (ii) biological (probability of transmission, treatment effectiveness, etc.); (iii) behavioural (number of sexual partners, condom use, etc.) and (iv) national response (testing, antiretroviral coverage, etc.).
The model will then be calibrated within a Bayesian framework to identify the model parameters that best reproduce HIV epidemic trends in the different subgroups, as well as the evolution of the coverage of interventions (e.g., condom use and treatment uptake).
Simulations and analyses
Once the three models have been parameterised and calibrated, they will be used to reproduce different hypothetical or observed scenarios:
The ATLAS programme as implemented
The screening programme without the implementation of ATLAS
Various ATLAS scaling scenarios (determined with the economic component)
Last, we compare costs (Cost Study WP) with expected epidemiological impacts to estimate the cost-effectiveness of these scaling scenarios.
Participants and public involvement
At each stage of the research implementation, communities were involved in the research programme. Stakeholders and local Civil Society Organisations (CSO) participated in programme development workshops which helped to develop the research questions.
Throughout the project, communities, stakeholders and local CSO will be consulted at least once a year through the consortium meetings that bring together all to discuss the progress, results and interpretation of the research. A representative of the Ministry of Health of each country is also associated with the research team which meets annually.
No HIVST kits will be distributed as part of the research activities of this protocol, as all HIVST kits under the ATLAS programme are provided as part of routine testing activities validated by the national AIDS programme of the country involved.
There should be no risk or consequence whatsoever associated with the refusal to participate in one, several or all of the proposed studies. In no way will participation or non-participation in any of the studies conducted impact (positively or negatively) access to HIVST kits. Participation in research will be voluntary.
There is no major individual health risk to participate in these studies. The primary risk is social; if one respondent sees another person participating in this study, he or she may make assumptions about his or her serological status and/or practices, which may be illegal (sex work, sex between men, drug use, etc.) and reveal them to the community. Measures are put in place to avoid this: interviews will be conducted in confidential places, data will be coded and kept in safe places, and records will be destroyed at the end of the project.
A website dedicated to the ATLAS programme (https://atlas.solthis.org) allows participants in the different studies to access the research protocol, the different information records of each study, and the results when they are available.
ATLAS is the first comprehensive study on HIV self-testing in West Africa. The ATLAS programme focuses particularly on the secondary distribution of HIVST. This study will also be the first to analyse the use of HIV self-testing among people who use injectable drugs in Africa. This is a multidisciplinary study that employs both qualitative and quantitative methods.
ATLAS research is an innovative approach to document HIV self-testing use, interfering as less as possible with routine activities and without actively tracking HIVST users to preserve confidentiality and anonymity.
The ATLAS protocol version 2.1 has been reviewed and approved by the following ethical committees:
Comité National d’Ethique des Sciences de la vie et de la santé de Côte d’Ivoire (ref: 049–19/MSHP/CNESVS-kp, 28th May 2019),
Comité d’Éthique de la Faculté de Médecine et de Pharmacie de l’université de Bamako Mali (ref: 2019/88/CE/FMPOS, 14th August 2019),
Comité National d’Ethique pour la Recherche en Santé du Sénégal (ref: SEN19/32, 26th July 2019),
Ethical Research Committee of the World Health Organisation (ERC 0003181, 7th August 2019),
LSTHM IRB (ref: 17141, 25th April 2019).
Our consent procedures include (i) signed consent form for face-to-face in-depth interviews, focus groups and time and motion study; (ii) specific consent obtained for audio recording interviews; (iii) authorisation of the manager of the dispensing sites and consent of the caregivers for the ethnographic studies and bottom-up cost; and (iv) anonymous time-stamped oral verbal consent for phone surveys.
Data monitoring plan
A data monitoring plan (DMP) has been developed and specifies the list of data collected in the framework of ATLAS research, their documentation and metadata, ethical and legal aspects, data storage and backup, intellectual property rights, a reminder of ethical aspects, rules for sharing, disseminating and reusing data, and rules for archiving and data preservation. This data management plan is publicly available on the Opidor platform: https://dmp.opidor.fr/plans/3354/export.pdf and is compliant with the European General Data Protection Regulation.
Availability of data and materials
The data management plan is publicly available on the Opidor platform: https://dmp.opidor.fr/plans/3354/export.pdf and is compliant with the European General Data Protection Regulation.
Civil Society Organisations
Data Monitoring Plan
Female Sex Workers
HIV testing services
Men who have Sex with Men
People Living with HIV
People Who use Injectable Drugs
Sexually transmitted infections
World Health Organisation
UNAIDS. Epidemiological estimates. 2020. Available from: https://aidsinfo.unaids.org
Boily M-C, Pickles M, Alary M, Baral S, Blanchard J, Moses S, et al. What really is a concentrated HIV epidemic and what does it mean for west and central Africa? Insights from mathematical modeling. JAIDS J Acquir Immune Defic Syndr. 2015;68:S74–82.
UNAIDS. 2020 Global AIDS update — seizing the moment — tackling entrenched inequalities to end epidemics; 2020. p. 384.
WHO. Regional workshop on differentiated approaches for HIV testing services in west and central Africa Meeting report. Dakar; 2017. Available from: https://www.who.int/hiv/pub/meetingreports/wca-hiv-testing-workshop/en/
Stahlman S, Beyrer C, Sullivan PS, Mayer KH, Baral SD. Engagement of gay men and other men who have sex with men (MSM) in the response to HIV: a critical step in achieving an AIDS-free generation. AIDS Behav. 2016;20(S3):330–40.
Nnko S, Kuringe E, Nyato D, Drake M, Casalini C, Shao A, et al. Determinants of access to HIV testing and counselling services among female sex workers in sub-Saharan Africa: a systematic review. BMC Public Health. 2019;19(1):15.
Fay H, Baral SD, Trapence G, Motimedi F, Umar E, Iipinge S, et al. Stigma, health care access, and HIV knowledge among men who have sex with men in Malawi, Namibia, and Botswana. AIDS Behav. 2011;15(6):1088–97.
Broqua C. Les formes sociales de l’homosexualité masculine à Bamako dans une perspective comparée : entre tactiques et mobilisations collectives. Polit Soc. 2012;31(2):113.
Stannah J, Dale E, Elmes J, Staunton R, Beyrer C, Mitchell KM, et al. HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis. Lancet HIV. 2019;6(11):e769–87.
Baral S, Rao A, Sullivan P, Phaswana-Mafuya N, Diouf D, Millett G, et al. The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment. Lancet HIV. 2019;6(9):e632–8.
UNAIDS. New HIV Infections by mode of transmission in West Africa: A MultiCountry Analysis. 2010.
Maheu-Giroux M, Vesga JF, Diabaté S, Alary M, Baral S, Diouf D, et al. Changing dynamics of HIV transmission in Côte dʼIvoire: modeling who acquired and transmitted infections and estimating the impact of past HIV interventions (1976–2015). JAIDS J Acquir Immune Defic Syndr. 2017;75(5):517–27.
Mukandavire C, Walker J, Schwartz S, Boily M-C, Danon L, Lyons C, et al. Estimating the contribution of key populations towards the spread of HIV in Dakar, Senegal. J Intern AIDS Soc. 2018;21:e25126.
Indravudh PP, Sibanda EL, d’Elbée M, Kumwenda MK, Ringwald B, Maringwa G, et al. ‘I will choose when to test, where I want to test’: investigating young peopleʼs preferences for HIV self-testing in Malawi and Zimbabwe. AIDS. 2017;31:S203–12.
Pant Pai N, Sharma J, Shivkumar S, Pillay S, Vadnais C, Joseph L, et al. Supervised and Unsupervised Self-Testing for HIV in High- and Low-Risk Populations: A Systematic Review. Weiser SD, editor. PLoS Med. 2013;10(4):e1001414.
Kalibala S, Tun W, Cherutich P, Nganga A, Oweya E, Oluoch P. Factors associated with acceptability of HIV self-testing among health Care Workers in Kenya. AIDS Behav. 2014;18(S4):405–14.
Knight L, Makusha T, Lim J, Peck R, Taegtmeyer M, van Rooyen H. “I think it is right”: a qualitative exploration of the acceptability and desired future use of oral swab and finger-prick HIV self-tests by lay users in KwaZulu-Natal, South Africa. BMC Res Notes. 2017;10(1).
Hector J, Davies M-A, Dekker-Boersema J, Aly MM, Abdalad CCA, Langa EBR, et al. Acceptability and performance of a directly assisted oral HIV self-testing intervention in adolescents in rural Mozambique. Yotebieng M, editor. PLoS ONE. 2018;13(4):e0195391.
Smith P, Wallace M, Bekker L-G. Adolescents’ experience of a rapid HIV self-testing device in youth-friendly clinic settings in Cape Town South Africa: a cross-sectional community based usability study. J Int AIDS Soc. 2016;19(1):21111.
Chanda MM, Ortblad KF, Mwale M, Chongo S, Kanchele C, Kamungoma N, et al. HIV self-testing among female sex workers in Zambia: A cluster randomized controlled trial. Bekker L-G, editor. PLoS Med. 2017;14(11):e1002442.
Ortblad KF, Kibuuka Musoke D, Ngabirano T, Nakitende A, Taasi G, Barresi LG, et al. HIV self-test performance among female sex workers in Kampala, Uganda: a cross-sectional study. BMJ Open. 2018;8(11):e022652.
Oldenburg CE, Ortblad KF, Chanda MM, Mwale M, Chongo S, Kanchele C, et al. Intimate partner violence and antiretroviral therapy initiation among female sex workers newly diagnosed with HIV in Zambia: a prospective study. J Acquir Immune Defic Syndr. 2018;79(4):5.
Thirumurthy H, Masters SH, Mavedzenge SN, Maman S, Omanga E, Agot K. Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study. Lancet HIV. 2016;3(6):e266–74.
Maman S, Murray KR, Napierala Mavedzenge S, Oluoch L, Sijenje F, Agot K, et al. A qualitative study of secondary distribution of HIV self-test kits by female sex workers in Kenya. Newman PA, editor. PLoS ONE. 2017;12(3):e0174629.
Lippman SA, Lane T, Rabede O, Gilmore H, Chen Y-H, Mlotshwa N, et al. High acceptability and increased HIV-testing frequency after introduction of HIV self-testing and network distribution among south African MSM. JAIDS J Acquir Immune Defic Syndr. 2018;77(3):279–87.
Johnson CC, Corbett EL. HIV self-testing to scale up couples and partner testing. Lancet HIV. 2016;3(6):e243–4.
Choko AT, Corbett EL, Stallard N, Maheswaran H, Lepine A, Johnson CC, et al. HIV self-testing alone or with additional interventions, including financial incentives, and linkage to care or prevention among male partners of antenatal care clinic attendees in Malawi: An adaptive multi-arm, multi-stage cluster randomised trial. Geng EH, editor. PLoS Med. 2019;16(1):e1002719.
Masters SH, Agot K, Obonyo B, Napierala Mavedzenge S, Maman S, Thirumurthy H. Promoting partner testing and couples testing through secondary distribution of HIV self-tests: a randomized clinical trial. Tsai AC, editor. PLoS Med. 2016;13(11):e1002166.
Chemaitelly H, Awad SF, Shelton JD, Abu-Raddad LJ. Sources of HIV incidence among stable couples in sub-Saharan Africa. J Int AIDS Soc. 2014;17(1).
Eyawo O, de Walque D, Ford N, Gakii G, Lester RT, Mills EJ. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(11):770–7.
Collignon R, Gruénais M-E, Vidal L, editors. L’annonce de la séropositivité au VIH en Afrique. Psychopathologie Africaine. 1994;26(2):291.
Gruénais M-É. Qui informer? Médecins, familles, tradipraticiens et religieux au Congo. Psychopathol Africaine. 1994;26(2):189–209.
Bott S, Obermeyer CM. The social and gender context of HIV disclosure in sub-Saharan Africa: A review of policies and practices. SAHARA-J J Soc Aspects HIV/AIDS. 2013;10(sup1):S5–16.
Obermeyer CM, Sankara A, Bastien V, Parsons M. Genre et expérience du dépistage du VIH au Burkina Faso. In: Les femmes à l’épreuve du VIH dans les pays du Sud : genre et accès universel à la prise en charge. Paris: ANRS; 2011. p. 17–30. (Sciences Sociales et Sida).
Coutherut J, Desclaux A. Le partage du statut sérologique avec l’entourage : Taverne B., Desclaux A., Sow P. S., Delaporte E., Ndoye I. Evaluation de l’impact bioclinique et social, individuel et collectif, du traitement ARV chez des patients VIH-1 pris en charge depuis 10 ans dans le cadre de l’ISAARV -Cohorte ANRS 1215. Rapport final. 2012. <halshs-00713030>.
Choko AT, Kumwenda MK, Johnson CC, Sakala DW, Chikalipo MC, Fielding K, et al. Acceptability of woman-delivered HIV self-testing to the male partner, and additional interventions: a qualitative study of antenatal care participants in Malawi. J Int AIDS Soc. 2017;20(1):21610.
Traoré T, Annick. Pourquoi et comment en parler ? Dialogue conjugal autour de l’annonce de la séropositivité dans des couples sérodiscordants à Abidjan (Côte d’Ivoire). Sci Soc Santé. 2006;24(2):43–67.
Kumwenda MK, Corbett EL, Chikovore J, Phiri M, Mwale D, Choko AT, et al. Discordance, disclosure and normative gender roles: barriers to couple testing within a community-level HIV self-testing intervention in urban Blantyre, Malawi. AIDS Behav. 2018;22(8):2491–9.
Rosenberg NE, Kamanga G, Pettifor AE, Bonongwe N, Mapanje C, Rutstein SE, et al. STI patients are effective recruiters of undiagnosed cases of HIV: results of a social contact recruitment study in Malawi. J Acquir Immune Defic Syndr. 2014;65(5):8.
Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect. 2011;87(3):183–90.
Inghels M, Kouassi AK, Niangoran S, Bekelynck A, Carillon S, Sika L, et al. Cascade of provider-initiated human immunodeficiency virus testing and counselling at specific life events (pregnancy, sexually transmitted infections, marriage) in Côte dʼIvoire. Sex Transm Dis. 2020;47(1):54–61.
Vu L, Andrinopoulos K, Tun W, Adebajo S. High levels of unprotected anal intercourse and never testing for HIV among men who have sex with men in Nigeria: evidence from a cross-sectional survey for the need for innovative approaches to HIV prevention. Sex Transm Infect. 2013;89(8):659–65.
Brown B, Folayan MO, Imosili A, Durueke F, Amuamuziam A. HIV self-testing in Nigeria: public opinions and perspectives. Glob Public Health. 2015;10(3):354–65.
Lyons CE, Coly K, Bowring AL, Liestman B, Diouf D, Wong VJ, et al. Use and acceptability of HIV self-testing among first-time testers at risk for HIV in Senegal. AIDS Behav. 2019;23(S2):130–41.
Kelvin EA, George G, Mwai E, Kinyanjui S, Romo ML, Odhiambo JO, et al. A randomized controlled trial to increase HIV testing demand among female sex workers in Kenya through announcing the availability of HIV self-testing via text message. AIDS Behav. 2019;23(1):116–25.
STAR project. Available from: http://hivstar.lshtm.ac.uk/
Ky-Zerbo O. Enjeux et limites du conseil et du test du VIH (CTV) dans un pays de basse prévalence en Afrique Subsaharienne : cas du Burkina Faso [Doctorat de santé publique]. [Montpellier]: Montpellier; 2016.
Glaser BG, Strauss AL. La découverte de la théorie ancrée: stratégies pour la recherche qualitative. Paris: Armand Colin; 2010. p. 409.
Scott JW. Gender: a useful category of historical analysis. Am Hist Rev. 1986;91(5):1053–75.
Vassal A, Sweeney S, Kahn JG, Gomez G, Bollinger L, Marseille E, et al. Reference case for estimating the costs of global health services and interventions: GHCC; 2017. p. 91. [cited 2019 Mar 14]. Available from: https://ghcosting.org/pages/standards/reference_case
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
Maheu-Giroux M, Vesga JF, Diabaté S, Alary M, Baral S, Diouf D, et al. Population-level impact of an accelerated HIV response plan to reach the UNAIDS 90-90-90 target in Côte d’Ivoire: insights from mathematical modeling. PLoS Med. 2017;14(6):e1002321.
Maheu-Giroux M, Diabaté S, Boily M-C, Jean-Paul N, Vesga JF, Baral S, et al. Cost-effectiveness of accelerated HIV response scenarios in Côte d’Ivoire. J Acquir Immune Defic Syndr. 2019;80(5):10.
The authors thank all the participants, and the operational field workers in Côte d’Ivoire, Mali and Senegal.
Boily Marie-Claude. Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
Desclaux Alice. Institut de Recherche pour le Développement, Transvihmi (UMI 233 IRD, 1175 INSERM, Montpellier University), Montpellier, France / CRCF, Dakar, Sénégal.
Larmarange Joseph. Centre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Pourette Dolorès. Centre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Terris-Prestholt F ern. Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Abdelaye Keita. Institut National de Recherche en Santé Publique, Bamako, Mali.
Arlette Simo Fotso. Centre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Arsène Kouassi Kra. Centre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Bekelynck Anne. Programme PACCI, ANRS Research Site, Treichville University Hospital, Abidjan, Côte d’Ivoire.
Breton Guillaume. Solthis, Paris, France.
d 'Elbée Marc. Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Desgree du Lou Annabel. Centre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Elvis Georges Amani. Programme PACCI, ANRS Research Site, Treichville University Hospital, Abidjan, Côte d’Ivoire.
Jean Kévin. Laboratoire MESuRS, Conservatoire National des Arts et Métiers, Paris, France.
Ky-zerbo Odette. TransVIHMI, IRD, Université de Montpellier, INSERM.
Kéba Badiane. Solthis, Sénégal.
Maheu-Giroux Mathieu. Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montréal, QC, H3A 1A2, Canada.
Moh Raoul. 1. Programme PACCI, ANRS Research Site, Treichville University Hospital, Abidjan, Côte d’Ivoire. 2. Department of Infectious and Tropical Diseases, Treichville University Teaching Hospital, Abidjan, Côte d’Ivoire. 3. Medical School, University Felix Houphouet Boigny, Abidjan, Côte d’Ivoire.
Mosso Rosine. ENSEA Ecole Nationale de Statistiques et d’Economie Appliquée, Abidjan, Côte d’Ivoire.
Métogara Mohamed Traore. Solthis, Côte d’Ivoire.
Paltiel David. Yale School of Public Health, New Haven, CT, USA.
Pr Eboi EHUI. Directeur Coordonnateur, PNLS.
Silhol Romain. Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom.
Rouveau Nicolas. Centre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Sokhna Boye. Centre Population et Développement, Institut de Recherche pour le Développement, Université Paris Descartes, Inserm, Paris, France.
Clémence Doumenc- Aïdara. Solthis, Dakar, Sénégal.
Dr. Sanata D iallo. Solthis, Dakar, Sénégal.
Odé KANKU K ABEMBA. Solthis, Bamako, Mali.
Olivier Geoffroy. Solthis, Abidjan, Côte d’Ivoire.
Vautier Anthony. Solthis, Dakar, Sénégal.
Alain-Michel KPOLO. Directeur Exécutif, Ruban Rouge, Côte d’Ivoire.
Dr Annie DIOKOURI. Conseillère Technique, Fondation Ariel Glaser, Côte d’Ivoire.
Dr Armand ABOKON. Directeur Exécutif, Fondation Ariel Glaser, Côte d’Ivoire.
Dr Blaise KOUAME. Service Dépistage, PNLS.
Dr Camille ANOMA. Directeur Exécutif, Espace Confiance, Côte d’Ivoire.
Dr Venance KOUAKOU. Directeur pays, Heartland Alliance, Côte d’Ivoire.
KOFFI Odette. Aprosam, Côte d’Ivoire.
TETY Josiane. Blety, Côte d’Ivoire.
TRAORE Yacouba. ORASUR, Côte d’Ivoire.
Abdoulaye S ANOGO. Amprode Sahel, Mali.
Daouda Diakite. Secrétariat Exécutif du Haut Conseil National de Lutte contre le Sida, Mali.
Djelika Berthé. PSI, Mali.
Dr Camara Adam Yattassaye. Arcad-Sida, Mali.
Dr Dembele Bintou Keita. Arcad-Sida, Mali.
Dr Dramane Koné. Secrétariat Exécutif du Haut Conseil National de Lutte contre le Sida, Mali.
Dr Jules Bagendabanga. FHI 360, Mali.
Dr KEITA Aminata Saran. Soutoura, Mali.
Dr Septime H essou. Plan Mali.
Dr Telly Nouhoum. CSLS/MSHP.
Fadiala Sidibé. Soutoura, Mali.
Kanoute Abdul Karim. Plan Mali.
Madani Tall. FHI 360, Mali.
Mahamadou DIAKITE. Danayaso, Mali.
Maiga Almoustapha. Comité scientifique VIH.
Mariam Koné. AKS, Mali.
Prof Minta D aouda. Comité scientifique VIH.
Saidou Kanambaye. PSI, Mali.
Youssouf Diallo. CSLS/MSHP.
Dr Alassane Moussa Niang. DLSI, Ministère de la Santé et de l’action sociale, Sénégal.
Dr Fatou Fall. DLSI, Ministère de la Santé et de l’action sociale, Sénégal.
Dr Idrissa Bâ. CEPIAD, Sénégal.
Dr NDèye Fatou NGom Guèye. CTA, Sénégal.
Dr Oumar Samba. CEPIAD, Sénégal.
Dr Papa Amadou Niang. CNLS, Sénégal.
Dr Safiatou Thiam. CNLS, Sénégal.
Nguissali M.E. Turpin. Enda Santé, Sénégal.
Sidy Mokhtar NDiaye. Enda Santé, Sénégal.
Brou Alexis Kouadio. Assistant de recherche, Côte d’Ivoire.
Cheick Sidi Camara. Assistant de recherche, Mali.
Sarrassat Sophie. Centre for Maternal Adolescent Reproductive and Child Health, London School of Hygiene and Tropical Medicine, London, UK.
Seydou Bouaré. Assistant de recherche, Mali.
Souleymane Sow. Assistant de recherche, Sénégal.
Pr. Ndour Cheikh Tidiane. Chef de la Division de Lutte contre le Sida et les IST, Ministère de la Santé et de l’Action Sociale Institut d’Hygiène Sociale, Dakar, Sénégal.
Our consent procedures include (i) signed consent form for face-to-face in-depth interviews, focus groups and time and motion study; (ii) specific consent obtained for audio recording interviews; (iii) authorisation of the manager of the dispensing sites and consent of the caregivers for the ethnographic studies and bottom-up cost; and (iv) anonymous time-stamped oral verbal consent for phone surveys.
For all studies except Coupons survey, participants must be aged 18 years old or more. For Coupons survey, the minimum age to participate is based on local legislation regarding HIV testing. The minimum age to get HIV tested without parental consent is 18 years old in Mali, 16 years old in Cote d’Ivoire (according to the law No. 2014–430 of 14 July 2014 of the Republic of Côte d’Ivoire) and 15 years old in Senegal (law No. 2010–03 of 9 April 2010 of the Republic of Senegal). Considering that the Coupons survey is an anonymous phone survey among HIVST users, the ethics committees have exempted us from collecting parental consent for minors who are legally entitled to be tested without parental consent, i.e. teenagers aged 15–17 in Senegal and teenagers aged 15–17 in Cote d’Ivoire.
This work was supported by Unitaid (grant number 2018–23-ATLAS) with additional funding from Agence Française pour le Developpement (AFD). The funders were not involved in the design of this study.
Ethics approval and consent to participate
The ATLAS protocol version 2.1 has been reviewed and approved by the following ethical committees:
• Comité National d’Ethique des Sciences de la vie et de la santé de Côte d’Ivoire (ref: 049–19/MSHP/CNESVS-kp, 28th May 2019),
• Comité d’Éthique de la Faculté de Médecine et de Pharmacie de l’université de Bamako Mali (ref: 2019/88/CE/FMPOS, 14th August 2019),
• Comité National d’Ethique pour la Recherche en Santé du Sénégal (ref: SEN19/32, 26th July 2019),
• Ethical Research Committee of the World Health Organisation (ERC 0003181, 7th August 2019),
• LSTHM IRB (ref: 17141, 25th April 2019).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Rouveau, N., Ky-Zerbo, O., Boye, S. et al. Describing, analysing and understanding the effects of the introduction of HIV self-testing in West Africa through the ATLAS programme in Côte d’Ivoire, Mali and Senegal. BMC Public Health 21, 181 (2021). https://doi.org/10.1186/s12889-021-10212-1
- HIV self-testing
- West Africa
- Côte d’Ivoire